annual CFF:
$249.25M+$196.09M(+368.82%)Summary
- As of today (July 6, 2025), EWTX annual cash flow from financing activities is $249.25 million, with the most recent change of +$196.09 million (+368.82%) on December 31, 2024.
- During the last 3 years, EWTX annual CFF has risen by +$62.87 million (+33.73%).
- EWTX annual CFF is now at all-time high.
Performance
EWTX Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$2.22M-$672.00K(-23.21%)Summary
- As of today (July 6, 2025), EWTX quarterly cash flow from financing activities is $2.22 million, with the most recent change of -$672.00 thousand (-23.21%) on March 31, 2025.
- Over the past year, EWTX quarterly CFF has dropped by -$238.85 million (-99.08%).
- EWTX quarterly CFF is now -99.08% below its all-time high of $241.07 million, reached on March 31, 2024.
Performance
EWTX quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$10.40M-$238.85M(-95.83%)Summary
- As of today (July 6, 2025), EWTX TTM cash flow from financing activities is $10.40 million, with the most recent change of -$238.85 million (-95.83%) on March 31, 2025.
- Over the past year, EWTX TTM CFF has dropped by -$283.81 million (-96.46%).
- EWTX TTM CFF is now -96.61% below its all-time high of $307.23 million, reached on March 31, 2021.
Performance
EWTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
EWTX Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +368.8% | -99.1% | -96.5% |
| 3 y3 years | +33.7% | +2945.2% | +2210.1% |
| 5 y5 years | +905.0% | +100.0% | +7605.9% |
EWTX Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +368.8% | -99.1% | +833.7% | -96.5% | +8489.5% |
| 5 y | 5-year | at high | +905.0% | -99.1% | +348.1% | -96.6% | +2210.1% |
| alltime | all time | at high | +905.0% | -99.1% | +348.1% | -96.6% | +2210.1% |
EWTX Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $2.22M(-23.2%) | $10.40M(-95.8%) |
| Dec 2024 | $249.25M(+368.8%) | $2.90M(-13.1%) | $249.25M(-16.7%) |
| Sep 2024 | - | $3.33M(+70.7%) | $299.35M(+1.2%) |
| Jun 2024 | - | $1.95M(-99.2%) | $295.80M(+0.5%) |
| Mar 2024 | - | $241.07M(+355.0%) | $294.22M(+453.4%) |
| Dec 2023 | $53.17M(-59.0%) | $52.99M(<-9900.0%) | $53.17M(<-9900.0%) |
| Sep 2023 | - | -$211.00K(-157.2%) | -$124.00K(-100.1%) |
| Jun 2023 | - | $369.00K(+1657.1%) | $129.78M(+0.1%) |
| Mar 2023 | - | $21.00K(-106.9%) | $129.59M(-0.0%) |
| Dec 2022 | $129.64M | -$303.00K(-100.2%) | $129.64M(-0.5%) |
| Sep 2022 | - | $129.69M(>+9900.0%) | $130.24M(>+9900.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | $179.00K(+145.2%) | $582.00K(-218.1%) |
| Mar 2022 | - | $73.00K(-75.1%) | -$493.00K(-100.3%) |
| Dec 2021 | $186.38M(+55.0%) | $293.00K(+691.9%) | $186.38M(-33.7%) |
| Sep 2021 | - | $37.00K(-104.1%) | $281.09M(-8.2%) |
| Jun 2021 | - | -$896.00K(-100.5%) | $306.20M(-0.3%) |
| Mar 2021 | - | $186.95M(+96.8%) | $307.23M(+155.4%) |
| Dec 2020 | $120.28M(+385.0%) | $95.00M(+277.9%) | $120.28M(+375.8%) |
| Sep 2020 | - | $25.14M(>+9900.0%) | $25.28M(>+9900.0%) |
| Jun 2020 | - | $135.00K(>+9900.0%) | $135.00K(>+9900.0%) |
| Mar 2020 | - | $0.00 | $0.00 |
| Dec 2019 | $24.80M | - | - |
FAQ
- What is Edgewise Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Edgewise Therapeutics?
- What is Edgewise Therapeutics annual CFF year-on-year change?
- What is Edgewise Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Edgewise Therapeutics?
- What is Edgewise Therapeutics quarterly CFF year-on-year change?
- What is Edgewise Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Edgewise Therapeutics?
- What is Edgewise Therapeutics TTM CFF year-on-year change?
What is Edgewise Therapeutics annual cash flow from financing activities?
The current annual CFF of EWTX is $249.25M
What is the all time high annual CFF for Edgewise Therapeutics?
Edgewise Therapeutics all-time high annual cash flow from financing activities is $249.25M
What is Edgewise Therapeutics annual CFF year-on-year change?
Over the past year, EWTX annual cash flow from financing activities has changed by +$196.09M (+368.82%)
What is Edgewise Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of EWTX is $2.22M
What is the all time high quarterly CFF for Edgewise Therapeutics?
Edgewise Therapeutics all-time high quarterly cash flow from financing activities is $241.07M
What is Edgewise Therapeutics quarterly CFF year-on-year change?
Over the past year, EWTX quarterly cash flow from financing activities has changed by -$238.85M (-99.08%)
What is Edgewise Therapeutics TTM cash flow from financing activities?
The current TTM CFF of EWTX is $10.40M
What is the all time high TTM CFF for Edgewise Therapeutics?
Edgewise Therapeutics all-time high TTM cash flow from financing activities is $307.23M
What is Edgewise Therapeutics TTM CFF year-on-year change?
Over the past year, EWTX TTM cash flow from financing activities has changed by -$283.81M (-96.46%)